The FDA on Wednesday approved Abbott Laboratories' Xience V drug-coated stent, which is expected to compete with Boston Scientific's Taxus and Johnson & Johnson's Cypher in the approximately $2 billion U.S. market for the devices. The clearance also allows Boston Scientific to launch Promus, a version of the Abbott-made stent.

Related Summaries